These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 11362207

  • 21. Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial.
    Ghosn J, Quinson AM, Sabo N, Cotte L, Piketty C, Dorléacq N, Bravo ML, Mayers D, Harmenberg J, Mårdh G, Valdez H, Katlama C.
    HIV Med; 2007 Apr; 8(3):142-7. PubMed ID: 17461857
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. ABT-387/r early access program expanded further.
    Res Initiat Treat Action; 1999 Dec; 5(5):22. PubMed ID: 11366887
    [Abstract] [Full Text] [Related]

  • 25. Conference looks at HIV drug resistance.
    Chang HE.
    GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
    [Abstract] [Full Text] [Related]

  • 26. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL.
    Antivir Ther; 1999 Mar; 4 Suppl 3():85-7. PubMed ID: 16021877
    [Abstract] [Full Text] [Related]

  • 32. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
    Vazquez E.
    Posit Aware; 1996 Mar; 7(6):8-9. PubMed ID: 11363983
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Detectable viral loads and slow development of resistance.
    Gadd C.
    IAPAC Mon; 2005 Oct; 11(10):295-6. PubMed ID: 16673496
    [No Abstract] [Full Text] [Related]

  • 37. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN, Feinberg J, Goodrich J, Pilson RS, Siemon-Hryczyk P.
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [Abstract] [Full Text] [Related]

  • 38. Top AIDS researchers' strategy for antiretroviral treatment.
    AIDS Alert; 1996 Sep; 11(9):97-100. PubMed ID: 11363728
    [Abstract] [Full Text] [Related]

  • 39. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [Abstract] [Full Text] [Related]

  • 40. Merck protease inhibitor available to persons with CD4 count 50 or less--must register by August 11.
    AIDS Treat News; 1995 Jul 21; (no 227):1-2. PubMed ID: 11362618
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.